secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013642
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q2 revenue $31M (+32% YoY), net loss narrows to $6.1M; raises FY revenue guidance to $110-116M
--------------------------------------------------------------------------------

- Revenue $31.0M, +32% YoY, including $1.5M one-time product/license benefit; 9% sequential growth.
- GAAP gross margin 61.7% vs 37.1%; non-GAAP gross margin 56.4% vs 29.1%.
- Net loss $6.1M vs $24.9M prior year; near break-even cash flow; cash $329.5M.
- Launched LucentAD blood test for Alzheimer's; positive Bio-Hermes study correlation with amyloid PET.
- FY 2023 revenue outlook raised to $110-116M; cash burn lowered to $30-35M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000155837023013642/0001558370-23-013642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000155837023013642/tmb-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer